This excerpt taken from the STXS 8-K filed Feb 27, 2009.
Item 8.01. Other Events.
On February 27, 2009, Biosense Webster, Inc., announced that the U.S. Food and Drug Administration has approved for marketing its NAVISTAR® RMT THERMOCOOL® Catheter for use with the Stereotaxis NIOBE® platform. Stereotaxis (NASDAQ: STXS) (Stereotaxis or the Company) has partnered with Biosense Webster, Inc. in the development of ablation catheters used with its NIOBE® Magnetic Navigation System. The NAVISTAR® RMT THERMOCOOL® Catheter for radiofrequency (RF) ablation is used with the NIOBE® Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment.
NAVISTAR and THERMOCOOL are registered trademarks of Biosense Webster, and NIOBE is a registered trademark of Stereotaxis.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.